Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3
Castle Biosciences, Inc. (NASDAQ: CSTL) will release its financial results for the first quarter ended March 31, 2023, on May 3, 2023, after market close. Management will conduct a conference call and webcast at 4:30 p.m. Eastern Time to discuss these results. Interested parties can access the live webcast through the Company's Investor Relations page, with a replay available afterward. Castle Biosciences provides innovative tests for skin cancers, uveal melanoma, Barrett’s esophagus, and mental health conditions, and is progressing with R&D for other high-need diseases, including therapies for psoriasis and atopic dermatitis.
- Upcoming financial results presentation may lead to positive market response.
- The company is actively developing tests for diseases with high clinical needs.
- None.
Company management will host a conference call and webcast to discuss its financial results at
Conference Call and Webcast Details
A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/614563599, or via the webcast link on the Investor Relations page of the Company’s website: https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the conference call start time. A replay of the webcast will be available following the conclusion of the conference call.
To access the live conference call via phone, please dial 1 833 470 1428 from
There will be a brief Question and Answer session following management commentary.
About
Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005260/en/
Investor Contact:
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source:
FAQ
When will Castle Biosciences release its Q1 2023 financial results?
What time is the conference call for Castle Biosciences' financial results?
Where can I access the Castle Biosciences webcast for their financial results?